Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 5, 2016, Pages 530-537

  Pozniak, Anton ^a   Arribas, Jose R ^b   Gathe, Joseph ^c   Gupta, Samir K ^d   Post, Frank A ^e   Bloch, Mark ^f   Avihingsanon, Anchalee ^g   Crofoot, Gordon ^h   Benson, Paul ⁱ   Lichtenstein, Kenneth ^j   Ramgopal, Moti ^k   Chetchotisakd, Ploenchan ^l   Custodio, Joseph M ^m   Abram, Michael E ^m   Wei, Xuelian ^m   Cheng, Andrew ^m   McCallister, Scott ^m   SenGupta, Devi ^m   Fordyce, Marshall W ^m  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Therapeutic Concepts   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f Holdsworth House Medical Practice   (Australia)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h Gordon Crofoot Research   (United States)

ⁱ Be Well Medical Center   (United States)

^j DEPARTMENT OF MEDICINE   (United States)

^k Midway Immunology and Research Center   (United States)

^l KHON KAEN UNIVERSITY   (Thailand)

^m GILEAD SCIENCES   (United States)

more..

Author keywords

Bone mineral density; Chronic kidney disease; Emtricitabine; HIV; Tenofovir alafenamide

Indexed keywords

COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; CREATININE; RAMIPRIL; VALSARTAN; VIRUS RNA; COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; QUINOLONE DERIVATIVE; TENOFOVIR;

ADULT; AGED; ALBUMINURIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BRONCHITIS; COMORBIDITY; COUGHING; CREATININE CLEARANCE; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; KIDNEY CYST; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OSTEOPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SPINE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; DRUG SUBSTITUTION; HIV INFECTIONS; MIDDLE AGED; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY;

ADULT; ALBUMINURIA; BONE DENSITY; COBICISTAT; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EMTRICITABINE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; QUINOLONES; RENAL INSUFFICIENCY; TENOFOVIR;

EID: 84949035010     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000908     Document Type: Article

References (28)

1. Wyatt CM. The kidney in HIV infection: beyond HIV-associated nephropathy. Top Antivir Med. 2012;20:106-110.
2. Choi AI, Li Y, Deeks SG, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651-658.
3. Ibrahim F, Hamzah L, Jones R, et al. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis. 2012;60:539-547.
4. Centers for Disease Control and Prevention (CDC). Estimated HIV Incidence in the United States, 2007-2010. 2012.
5. Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol. 2005;16:2412-2420.
6. Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007;21:2101-2103.
7. Linley L, Prejean J, Qian A, et al. Racial/ethnic disparities in HIV diagnoses among persons aged 50 years and older in 37 US States, 2005-2008. Am J Public Health. 2012;102:1527-1534.
8. Adekeye OA, Heiman HJ, Onyeabor OS, et al. The new invincibles: HIV screening among older adults in the U.S. PLoS One. 2012;7:e43618.
9. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898-1906.
10. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52: 3144-3160.
11. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165-1173.
12. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197: 102-108.
13. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-272.
14. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606-2615.
15. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367:20-29.
16. Gilead Sciences. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) US prescribing information. Available at: http:// www.gilead.com/pdf/stribild-pi.pdf. Accessed December 28, 2015.
17. Gilead Sciences. Emtriva (emtricitabine) US prescribing information. Available at: http://www.gilead.com/pdf/emtriva-pi.pdf. Accessed December 28, 2015.
18. Gilead Sciences. Atripla (efavirenz, emtricitabine, tenofovir disoproxil fumarate) US prescribing information. Available at: http://www.gilead. com/pdf/atripla-pi.pdf. Accessed December 28, 2015.
19. Cooper RD, Wiebe N, Smith N, et al. Systematic review and metaanalysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.
20. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867-875.
21. Morlat P, Vivot A, Vandenhende MA, et al, the Groupe D'epidemiologie Clinique du Sida en Aquitaine (Gecsa). Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLoS One. 2013;8: e66223.
22. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375:2073-2081.
23. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93-104.
24. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with allcause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341-1352.
25. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine Association of the infectious diseases Society of America. Clin Infect Dis. 2014;59:e96-138.
26. KDIGO Guideline Development Staff. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;84:622-623. v-150.
27. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617-622.
28. Billington S, Chung G, Brown C. Tenofovir abolishes Na+-dependent phosphate uptake in human proximal tubule cell monolayers. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, 2014. Abstract R6328.